{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:40:47Z","timestamp":1772210447385,"version":"3.50.1"},"reference-count":89,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.bcp.2010.05.001","type":"journal-article","created":{"date-parts":[[2010,5,13]],"date-time":"2010-05-13T20:38:05Z","timestamp":1273783085000},"page":"584-591","source":"Crossref","is-referenced-by-count":24,"title":["Targeted therapy of chronic myeloid leukemia"],"prefix":"10.1016","volume":"80","author":[{"given":"Con","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaoyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2010.05.001_bib1","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1002\/cncr.24440","article-title":"The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos","volume":"115","author":"Tefferi","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2010.05.001_bib2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2010.05.001_bib3","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2010.05.001_bib4","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/nrm1443","article-title":"Apoptosis and genomic instability","volume":"5","author":"Zhivotovsky","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bcp.2010.05.001_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1280","article-title":"Regulation of the c-Abl and Bcr-Abl tyrosine kinases","volume":"5","author":"Hantschel","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bcp.2010.05.001_bib6","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1091\/mbc.E02-06-0342","article-title":"Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain","volume":"14","author":"Saharinen","year":"2003","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.bcp.2010.05.001_bib7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/asheducation-2005.1.195","article-title":"A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases","author":"Vainchenker","year":"2005","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bcp.2010.05.001_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.beha.2006.11.005","article-title":"The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age","volume":"20","author":"Kaushansky","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bcp.2010.05.001_bib9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2010.05.001_bib10","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2007-05-089003","article-title":"Evidence for MPL W515L\/K mutations in hematopoietic stem cells in primitive myelofibrosis","volume":"110","author":"Chaligne","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2010.05.001_bib11","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/leu.2008.137","article-title":"New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1\/S-phase transition","volume":"22","author":"Chaligne","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2010.05.001_bib12","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bcp.2010.05.001_bib13","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2010.05.001_bib14","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMra0803109","article-title":"Chromosomal abnormalities in cancer","volume":"359","author":"Frohling","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2010.05.001_bib15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.tig.2005.10.002","article-title":"Causes of oncogenic chromosomal translocation","volume":"22","author":"Aplan","year":"2006","journal-title":"Trends Genet"},{"key":"10.1016\/j.bcp.2010.05.001_bib16","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia\u2014advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2010.05.001_bib17","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2010.05.001_bib18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/leu.2009.196","article-title":"The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis","volume":"24","author":"Demehri","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2010.05.001_bib19","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.yexcr.2009.11.014","article-title":"Novel role of pleckstrin homology domain of the Bcr-Abl protein: analysis of protein-protein and protein-lipid interactions","volume":"316","author":"Miroshnychenko","year":"2010","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.bcp.2010.05.001_bib20","doi-asserted-by":"crossref","first-page":"10282","DOI":"10.1073\/pnas.92.22.10282","article-title":"Abr and Bcr are multifunctional regulators of the Rho GTP-binding protein family","volume":"92","author":"Chuang","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2010.05.001_bib21","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance","volume":"145","author":"Kantarjian","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bcp.2010.05.001_bib22","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1182\/blood.V86.12.4603.bloodjournal86124603","article-title":"BCR\/ABL P210 and P190 cause distinct leukemia in transgenic mice","volume":"86","author":"Voncken","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2010.05.001_bib23","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.bcp.2010.05.001_bib24","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","article-title":"The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity","volume":"189","author":"Li","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.bcp.2010.05.001_bib25","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood.V88.7.2410.bloodjournal8872410","article-title":"Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR\/ABL with C3\/A2 junction)","volume":"88","author":"Pane","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2010.05.001_bib26","first-page":"320","article-title":"p230 does not always predict a mild clinical course in myeloid malignancies: e19a2 bcr\/abl fusion transcript with additional chromosome abnormalities in a patient with acute monoblastic leukemia (M5a)","volume":"86","author":"Bernasconi","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.bcp.2010.05.001_bib27","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1136\/jcp.2005.029595","article-title":"e19a2 BCR-ABL fusion transcript in typical chronic myeloid leukaemia: a report of two cases","volume":"59","author":"Mondal","year":"2006","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.bcp.2010.05.001_bib28","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1182\/blood.V90.12.5024","article-title":"Typical chronic myelogenous leukemia with e19a2 junction BCR\/ABL transcript","volume":"90","author":"Briz","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2010.05.001_bib29","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1182\/blood.V89.10.3889","article-title":"Relationship between BCR\/ABL fusion proteins and leukemia phenotype","volume":"89","author":"Emilia","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2010.05.001_bib30","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1182\/blood.V89.11.4239","article-title":"A new case of chronic myeloid leukemia with c3\/a2 BCR\/ABL junction. Is it really a distinct disease?","volume":"89","author":"Mittre","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2010.05.001_bib31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1517\/14728222.9.2.329","article-title":"Src kinases as targets for B cell acute lymphoblastic leukaemia therapy","volume":"9","author":"Li","year":"2005","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.bcp.2010.05.001_bib32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/10428190701713689","article-title":"Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia","volume":"49","author":"Li","year":"2008","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.bcp.2010.05.001_bib33","first-page":"3589","article-title":"Activation of Src kinases p53\/56lyn and p59hck by p210bcr\/abl in myeloid cells","volume":"56","author":"Danhauser-Riedl","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2010.05.001_bib34","doi-asserted-by":"crossref","first-page":"30907","DOI":"10.1074\/jbc.M605902200","article-title":"Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity","volume":"281","author":"Meyn","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2010.05.001_bib35","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ng1343","article-title":"Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia","volume":"36","author":"Hu","year":"2004","journal-title":"Nat Genet"},{"key":"10.1016\/j.bcp.2010.05.001_bib36","doi-asserted-by":"crossref","first-page":"16870","DOI":"10.1073\/pnas.0606509103","article-title":"Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice","volume":"103","author":"Hu","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2010.05.001_bib37","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/blood-2007-08-109330","article-title":"Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells","volume":"111","author":"Wu","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2010.05.001_bib38","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2010.05.001_bib39","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2010.05.001_bib40","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1038\/sj.onc.1204638","article-title":"Modeling Philadelphia chromosome positive leukemias","volume":"20","author":"Wong","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2010.05.001_bib41","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1038\/sj.onc.1205313","article-title":"Modelling haematopoietic malignancies in the mouse and therapeutical implications","volume":"21","author":"Bernardi","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2010.05.001_bib42","doi-asserted-by":"crossref","first-page":"8612","DOI":"10.1038\/sj.onc.1206089","article-title":"The biology of chronic myelogenous leukemia:mouse models and cell adhesion","volume":"21","author":"Wertheim","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2010.05.001_bib43","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.bcp.2010.05.001_bib44","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1073\/pnas.87.17.6649","article-title":"Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR\/ABL","volume":"87","author":"Kelliher","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2010.05.001_bib45","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/978-1-60761-058-8_15","article-title":"CML mouse model in translational research","volume":"602","author":"Peng","year":"2010","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.bcp.2010.05.001_bib46","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.bcp.2010.05.001_bib47","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2010.05.001_bib48","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0301-472X(00)00142-9","article-title":"The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia","volume":"28","author":"Marley","year":"2000","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bcp.2010.05.001_bib49","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2010.05.001_bib50","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrd2135","article-title":"Dasatinib","volume":"5","author":"Kantarjian","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bcp.2010.05.001_bib51","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2010.05.001_bib52","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nsmb.1486","article-title":"Activation of tyrosine kinases by mutation of the gatekeeper threonine","volume":"15","author":"Azam","year":"2008","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.bcp.2010.05.001_bib53","doi-asserted-by":"crossref","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2010.05.001_bib54","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/leu.2009.69","article-title":"The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR\/ABL","volume":"23","author":"Mian","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2010.05.001_bib55","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2010.05.001_bib56","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2010.05.001_bib57","doi-asserted-by":"crossref","first-page":"e7520","DOI":"10.1371\/journal.pone.0007520","article-title":"Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10)","volume":"4","author":"Shen","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2010.05.001_bib58","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1093\/emboj\/cdf562","article-title":"The Src family kinase Hck couples BCR\/ABL to STAT5 activation in myeloid leukemia cells","volume":"21","author":"Klejman","year":"2002","journal-title":"EMBO J"},{"key":"10.1016\/j.bcp.2010.05.001_bib59","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/sj.leu.2402778","article-title":"The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains","volume":"17","author":"Stanglmaier","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2010.05.001_bib60","doi-asserted-by":"crossref","first-page":"33260","DOI":"10.1074\/jbc.272.52.33260","article-title":"The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr","volume":"272","author":"Warmuth","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2010.05.001_bib61","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2010.05.001_bib62","first-page":"233","article-title":"Development and targeted use of nilotinib in chronic myeloid leukemia","volume":"2","author":"Fava","year":"2008","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.bcp.2010.05.001_bib63","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2010.05.001_bib64","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/442754a","article-title":"Cancer biology: a game of subversion","volume":"442","author":"Passegue","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2010.05.001_bib65","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/4351169a","article-title":"Cancer biology: summing up cancer stem cells","volume":"435","author":"Huntly","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2010.05.001_bib66","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrc1592","article-title":"Leukaemia stem cells and the evolution of cancer-stem-cell research","volume":"5","author":"Huntly","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bcp.2010.05.001_bib67","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia","volume":"435","author":"Michor","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2010.05.001_bib68","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","article-title":"Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications","volume":"12","author":"Roeder","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2010.05.001_bib69","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/asheducation-2008.1.436","article-title":"Chronic myeloid leukemia stem cells","author":"Jamieson","year":"2008","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bcp.2010.05.001_bib70","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nm1483","article-title":"Targeting of CD44 eradicates human acute myeloid leukemic stem cells","volume":"12","author":"Jin","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2010.05.001_bib71","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/nm1489","article-title":"Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells","volume":"12","author":"Krause","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2010.05.001_bib72","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood-2009-01-202606","article-title":"The leukemic stem cell niche: current concepts and therapeutic opportunities","volume":"114","author":"Lane","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2010.05.001_bib73","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1042\/BST0351347","article-title":"Characterization of cancer stem cells in chronic myeloid leukaemia","volume":"35","author":"Jorgensen","year":"2007","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.bcp.2010.05.001_bib74","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/leu.2008.262","article-title":"beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia","volume":"23","author":"Hu","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2010.05.001_bib75","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2009-06-228130","article-title":"PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice","volume":"115","author":"Peng","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2010.05.001_bib76","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2006-10-054098","article-title":"Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells","volume":"110","author":"Peng","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2010.05.001_bib77","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.4161\/cc.6.18.4722","article-title":"Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors","volume":"6","author":"Peng","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bcp.2010.05.001_bib78","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/ng.389","article-title":"Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia","volume":"41","author":"Chen","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.bcp.2010.05.001_bib79","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/sj.emboj.7600502","article-title":"5-Lipoxygenase regulates senescence-like growth arrest by promoting ROS-dependent p53 activation","volume":"24","author":"Catalano","year":"2005","journal-title":"EMBO J"},{"key":"10.1016\/j.bcp.2010.05.001_bib80","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/372179a0","article-title":"Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene","volume":"372","author":"Chen","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2010.05.001_bib81","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.tibs.2007.06.002","article-title":"5-Lipoxygenase: regulation of expression and enzyme activity","volume":"32","author":"Radmark","year":"2007","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.bcp.2010.05.001_bib82","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1038\/sj.onc.1205702","article-title":"Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway","volume":"21","author":"Taylor","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2010.05.001_bib83","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/nm1099","article-title":"The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm","volume":"10","author":"Zhao","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2010.05.001_bib84","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nrm2335","article-title":"Lipid signalling in disease","volume":"9","author":"Wymann","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bcp.2010.05.001_bib85","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1006\/abbi.2000.2168","article-title":"Leukotriene B4: metabolism and signal transduction","volume":"385","author":"Yokomizo","year":"2001","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.bcp.2010.05.001_bib86","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1172\/JCI200318338","article-title":"The organization and consequences of eicosanoid signaling","volume":"111","author":"Soberman","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2010.05.001_bib87","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1182\/blood-2003-09-3033","article-title":"Lack of the adhesion molecules P-selectin and intercellular adhesion molecule-1 accelerate the development of BCR\/ABL-induced chronic myeloid leukemia-like myeloproliferative disease in mice","volume":"104","author":"Pelletier","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2010.05.001_bib88","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1101\/gad.1600307","article-title":"Linking the hematopoietic microenvironment to imatinib-resistant Ph+ B-ALL","volume":"21","author":"Dorshkind","year":"2007","journal-title":"Genes Dev"},{"key":"10.1016\/j.bcp.2010.05.001_bib89","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1101\/gad.1588607","article-title":"Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia","volume":"21","author":"Williams","year":"2007","journal-title":"Genes Dev"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295210003400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295210003400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T16:36:58Z","timestamp":1591288618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295210003400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":89,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0006295210003400"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2010.05.001","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}